NCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
Clinical Trials
12 trialsNCT03706365 2025-04-20
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting
NCT03822845 2025-04-17
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03389451 2024-07-12
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03388346 2024-02-15
68Ga PSMA in Preprostatectomy Patients
University of Iowa
Phase 2/3 Completed
NCT03103152 2023-03-29
PROVENT
Queen Mary University of London
Phase 2/3 Completed
NCT02673151 2022-01-13
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Phase 2/3 Completed
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT01603420 2016-03-14
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
Phase 2/3 Terminated
NCT00215683 2015-04-01
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT01715064 2014-02-10
Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients
University of Guelph-Humber
Phase 2/3 Completed
NCT00268892 2010-12-24
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed